Abstract:Maheswari Muruganandam, Angie Ariza-Hutchinson, Rosemina A Patel, Wilmer L Sibbitt Jr Department of Internal Medicine, Division of Rheumatology and School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA Correspondence: Maheswari Muruganandam, Department of Internal Medicine, Division of Rheumatology and School of Medicine, University of New Mexico Health Sciences Center, MSC 10 5550, 5th FL ACC, Albuquerque, NM, 87131, USA, Tel +1 (505) 272-4761, Fax +1 (505) 272-3624, Email Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, vasoinstability, and decreased perfusion with ischemia, inflammation, and exuberant fibrosis of the skin and internal organs. Biomarkers are analytic indicators of the biological and disease processes within an individual that can be accurately and reproducibly measured. The field of biomarkers in SSc is complex as recent studies have implicated at least 240 pathways and dysregulated proteins in SSc pathogenesis. Anti-nuclear antibodies (ANA) are classical biomarkers with well-described clinical classifications and are present in more than 90% of SSc patients and include anti-centromere, anti-Th/To, anti-RNA polymerase III, and anti-topoisomerase I antibodies. Transforming growth factor-β (TGF-β) is central to the fibrotic process of SSc and is intimately intertwined with other biomarkers. Tyrosine kinases, interferon-1 signaling, IL-6 signaling, endogenous thrombin, peroxisome proliferator-activated receptors (PPARs), lysophosphatidic acid receptors, and amino acid metabolites are new biomarkers with the potential for developing new therapeutic agents. Other biomarkers implicated in SSc-ILD include signal transducer and activator of transcription 4 (STAT4), CD226 (DNAX accessory molecule 1), interferon regulatory factor 5 (IRF5), interleukin-1 receptor–associated kinase-1 (IRAK1), connective tissue growth factor (CTGF), pyrin domain containing 1 (NLRP1), T-cell surface glycoprotein zeta chain (CD3ζ) or CD247, the NLR family, SP-D (surfactant protein), KL-6, leucine-rich α 2-glycoprotein-1 (LRG1), CCL19, genetic factors including DRB1 alleles, the interleukins (IL-1, IL-4, IL-6, IL-8, IL-10 IL-13, IL-16, IL-17, IL-18, IL-22, IL-32, and IL-35), the chemokines CCL (2,3,5,13,20,21,23), CXC (8,9,10,11,16), CX3CL1 (fractalkine), and GDF15. Adiponectin (an indicator of PPAR activation) and maresin 1 are reduced in SSc patients. A new trend has been the use of biomarker panels with combined complex multifactor analysis, machine learning, and artificial intelligence to determine disease activity and response to therapy. The present review is an update of the various biomarker molecules, pathways, and receptors involved in the pathology of SSc. Keywords: biomarker, systemic sclerosis, scleroderma, cytokine, autoantibody Biomarkers are analytic indicators of the presence of a biological or disease process and/or activity of that process within an individual that can be accurately and reproducibly measured. 1–11 Thus, a biomarker could be a physical measure such as blood pressure, a cytokine such as IL-1, a cell or cellular manifestation such as a membrane receptor, a metabolite such lactate, or other reproducible indicator of a biologic or medical process. Biomarkers have become an increasingly important aspect of systemic sclerosis (SSc) research and clinical care. 12 The field of biomarkers in SSc is complex and evolving as recent studies have implicated at least 240 pathways and numerous dysregulated proteins in the pathogenesis of SSc. 5–14 SSc is a complex autoimmune disease characterized by prominent fibrosis of the skin, macro- and micro-vascular damage, vasoinstability, and decreased peripheral blood perfusion with ischemia, inflammation, and exuberant fibrosis of internal organs including the lungs, kidneys, bowel, heart, and esophagus. 15–17 The presence of skin thickening of the fingers extending proximal to the metacarpophalangeal joint is adequate to be classified as SSc. However, if proximal skin thickening is not present, the weighted addition of the following findings: skin thickening of the fingers, finger tip lesions (ischemic ulcerations or pitting scars), telangiectasia, abnormal nail fold capillaries, interstitial lung disease, pulmonary arterial hypertension, Raynaud's phenomenon, and/or SSc-related autoantibodies (Table 1) may still permit the diagnosis of SSc. 18 SSc is presently formally classified into two main forms: 1) limited cutaneous SSc characterized by mostly distal skin thickening and the presence of anti-centromere antibodies (Figure 1), and 2) diffuse cutaneous SSc with widespread distal and proximal cutaneous changes usually with the presence of anti-topoisomerase antibodies, anti-RNA-III polymerase antibodies or other anti-nucl -Abstract Truncated-

Nodular scleroderma: Characterization of a distinct clinical phenotype

Pulmonary Nodules in Juvenile Systemic Sclerosis: A Case-Series from the National Registry for Childhood Onset Scleroderma (NRCOS)

Pemphigoid nodularis: a report of three cases and review of the literature

A Fleshy Mystery: Prurigo Nodularis

Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma

Nodular Subtype of Bullous Pemphigoid

S4827 Severe Scleroderma Presenting With High Grade Distal Small Bowel Obstruction

Distinct T cell chromatin landscapes in scleroderma subtypes

Localized Scleroderma of Lower Extremities:Clinical and Magnetic Resonance Imaging Features.

Systemic sclerosis in adults. Part I: Clinical features and pathogenesis

Cutaneous Syncytial Myoepithelioma: An Uncommon and Distinct Variant of Cutaneous Epithelioid Neoplasm

Case Report: Pemphigoid Nodularis-Five Patients With Many Years of Follow-Up and Review of the Literature

Characterization of Endothelial Cell Subclusters in Localized Scleroderma Skin with Single-Cell RNA Sequencing Identifies NOTCH Signaling Pathway

Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis

[Localized scleroderma]

Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India

Prurigiform Angiomatosis: A New Term for Describing the Prominent Dermal Angiomatoid Proliferation Underlying Epidermal Changes in Prurigo Nodularis/Lichen Simplex Chronicus

Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

Single-Cell RNA-Sequencing Analyses Identify APLNR, INS-IGF2, RGCC Genes May Be Involved in the Pathogenesis of Systemic Sclerosis Skin

New Alternative Therapy for Orofacial Localized Scleroderma

Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis